The program addresses a recurring challenge in drug development where promising in vitro or rodent results lack sufficient non-human primate verification. By shifting safety evaluations earlier in the development lifecycle, HKeyBio aims to provide developers with actionable data on tolerability, immune-related risks, and pharmacokinetic profiles. The service targets a diverse range of modalities, including bispecific antibodies, ADCs, and cell therapies.

While these studies are explicitly non-GLP and do not replace formal IND-enabling toxicology, they serve as a critical risk-management tool. The framework allows for customizable modules, such as immune-cell subset analysis and cytokine screening, which are particularly relevant for immunomodulatory drugs. With research facilities operating in Suzhou and Guangxi, HKeyBio leverages an existing infrastructure that has already supported over 500 IND-related studies. This move expands the company’s diagnostic capabilities, effectively bridging the transition from early proof-of-concept research to the final stages of pre-clinical development.